Pirfenidone

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 2384 publications

Discovery of artemargyins A-E: rare 9'-nor-dibenzylbutane lignans and a lignan-coumarin hybrid with anti-hepatic fibrosis activities from Artemisia argyi var. gracilis.

Discovery of artemargyins A-E: rare 9'-nor-dibenzylbutane lignans and a lignan-coumarin hybrid with anti-hepatic fibrosis activities from Artemisia argyi var. gracilis.

Journal: Organic & biomolecular chemistry

Published: April 07, 2026

Agent-Based Modeling of Idiopathic Lung Fibrosis and Mechanistic Treatments.

Agent-Based Modeling of Idiopathic Lung Fibrosis and Mechanistic Treatments.

Journal: bioRxiv : the preprint server for biology

Published: April 03, 2026

Successful and practical pirfenidone desensitization.

Successful and practical pirfenidone desensitization.

Journal: Tuberkuloz ve toraks

Published: March 27, 2026

The mechanism of Rap1GAP in ventricular hypertrophy and interstitial fibrosis induced by angiotensin Ⅱ

The mechanism of Rap1GAP in ventricular hypertrophy and interstitial fibrosis induced by angiotensin Ⅱ

Journal: Zhonghua xin xue guan bing za zhi

Published: March 22, 2026

Evaluation of Pirfenidone for the Treatment of Acute Respiratory Distress Syndrome: A Case Report.

Evaluation of Pirfenidone for the Treatment of Acute Respiratory Distress Syndrome: A Case Report.

Journal: Journal of biosciences and medicines

Published: March 20, 2026

Visible-light-induced C-H trifluoromethylation of several nitrogen heterocycles with CF3Br.

Visible-light-induced C-H trifluoromethylation of several nitrogen heterocycles with CF3Br.

Journal: Organic & biomolecular chemistry

Published: February 19, 2026

Recent updates on engineered nanomedicines for treatment of fibrosis.

Recent updates on engineered nanomedicines for treatment of fibrosis.

Journal: Nanomedicine (London, England)

Published: February 18, 2026

A potent inhibitor of PAI-1, MDI-2517, mitigates disease severity in a preclinical systemic sclerosis model.

A potent inhibitor of PAI-1, MDI-2517, mitigates disease severity in a preclinical systemic sclerosis model.

Journal: JCI insight

Published: February 17, 2026

Detorsion is not innocent: pirfenidone prevents contralateral ovarian damage following ovarian torsion.

Detorsion is not innocent: pirfenidone prevents contralateral ovarian damage following ovarian torsion.

Journal: Naunyn-Schmiedeberg's archives of pharmacology

Published: February 17, 2026

Discovery of Marine Highly Congested Polycyclic Isodhilarane-Type Meroterpenoids as Potential Leads for Treating Liver Fibrosis by Activating the HSF1/AMPK Metabolic Axis.

Discovery of Marine Highly Congested Polycyclic Isodhilarane-Type Meroterpenoids as Potential Leads for Treating Liver Fibrosis by Activating the HSF1/AMPK Metabolic Axis.

Journal: Journal of medicinal chemistry

Published: February 16, 2026

Silicosis amelioration by chaetocin: a novel therapeutic strategy targeting the HIF1α-mediated PI3K/AKT/MMP9 pathway.

Silicosis amelioration by chaetocin: a novel therapeutic strategy targeting the HIF1α-mediated PI3K/AKT/MMP9 pathway.

Journal: International immunopharmacology

Published: February 15, 2026

Long-term Follow-up Results of Patients with Combined Pulmonary Fibrosis and Emphysema: A Single-Center Experience.

Long-term Follow-up Results of Patients with Combined Pulmonary Fibrosis and Emphysema: A Single-Center Experience.

Journal: Respiratory medicine

Published: February 03, 2026

Showing 1-12 of 2,384

Last Updated: 04/28/2026